LifeSciences BC > Anti-migraine Head Patch – HeadaTerm – Receives FDA Clearance

Anti-migraine Head Patch – HeadaTerm – Receives FDA Clearance

September 16th, 2018, Vancouver, BC – WAT Medical’s innovative technology to treat all primary headache, HeadaTerm, received its FDA clearance in September, 2018. This product, already approved by CE, HC, and now FDA, has been distributed in over 20 countries around the world. It has now officially entered the U.S. market as an effective treatment for migraine headache.

HeadaTerm uses precision Transcranial Electrical Stimulation (TENS) technology to target the pain receptors in the brain via neuromodulation. By sending a particular frequency of electrical stimulation, pain-relieving hormones like endorphin are released, which results in higher paintolerance against primary headaches. Studies have shown that insomnia is one of the common symptoms that show a positive correlation with migraine. Further research and clinical trials have revealed that for patients who experience both symptoms, relieving migraine also resulted in better sleep pattern, thus reducing insomnia. Depression is another common symptom that has been associated with migraine. Professor Mourad Tayebi, who specializes in Biomedical Sciences at the School of Medicine at Western Sydney University, has researched about this topic, and after studying the mechanism and interaction of HeadaTerm with the nerve nuceli, clinical evidence suggests that HeadaTerm could be used to treat patients who experience depression.

TENS has been studied extensively for the past few years, and many have shown that it has the potential to influence the visual cortex to improve spatial perception and modulation transfer function. Upcoming projects of WAT Medical could potentially focus on modifying the TENS technology used by HeadaTerm to target other areas of the body.

Contact: info@watmedical.com

References:

1. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm

2. https://www.ncbi.nlm.nih.gov/pubmed/16095269

3. https://doi.org/10.1162/jocn_a_00293